Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs SHP-659 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Parion Sciences
- 09 Aug 2017 Status changed from active, no longer recruiting to discontinued.
- 02 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
- 02 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.